Although Rhode Island is the smallest state in the United States, it had the fourth highest healthcare spend, which meant the state was spending "way too much" on healthcare, according to Beth Hebert-Silvia, RPh, managing director and assistant vice president of pharmacy at Blue Cross and Blue Shield of Rhode Island (BCBSRI).
Although Rhode Island is the smallest state in the United States, it had the fourth highest healthcare spend, which meant the state was spending “way too much” on healthcare, according to Beth Hebert-Silvia, RPh, managing director and assistant vice president of pharmacy at Blue Cross and Blue Shield of Rhode Island (BCBSRI).
At the Academy of Managed Care Pharmacy’s 27th Annual Meeting & Expo in San Diego, April 7-10, Ms Hebert-Silvia described the medication therapy management (MTM) model BCBSRI implemented with the help of OutcomesMTM.
The patient-centered medical home (PCMH) has proven to be the model that works the best in Rhode Island, she said. Looking ahead to what is needed to meet 2018 goals, the 3 keys to the success of the PCMH are: population health management, provider reimbursement, and analytics and reporting.
BCBSRI has struggled in the MTM space, Ms Herbert-Silvia admitted. It teamed with OutcomesMTM to help with the deployment of pharmacists, and the company enrolled all of its Medicare beneficiaries plus its commercial members who were older than 60 years of age. The membership was split into PCMH and network pharmacies.
“We all as health plans have the triple aim,” she said. “We want to decrease health care expenditures, we want to increase the member experience, and we want to increase our healthcare outcomes.”
Over 6 months that the MTM model was employed, BCBSRI realized $1.48 million through medical and pharmacy cost avoidance. Of the 48,403 Medicare members eligible, the model served 5092 for a total of 9313 MTM claims and 1456 claims for drug therapy problem resolutions. The engagement rate was 55% overall.
For its commercial members, engagement was lower at 41%, and BCBSRI realized $571,857 in savings.
The overall return on investment in the PCMH was $8.76 for every dollar spent and $6.61 for every dollar spent in the network model, Ms Herbert-Silvia reported.
Ruxolitinib Cream Shows Long-Term Safety in AD, Potential for PN Treatment
March 8th 2025Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream (Opzelura; Incyte) in atopic dermatitis (AD), while late-breaking research highlighted its potential efficacy in prurigo nodularis (PN).
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Shaping Dermatology's Future by Increasing Access, Data, and Advocacy
March 7th 2025Thy N. Huynh, MD, FAAD, Bruce A. Brod, MHCI, MD, FAAD, and Melissa Piliang, MD, FAAD, discussed expanding access to pediatric dermatology, dermatology data aggregation, and advocacy for Medicare physician payment reform, respectively.
Read More